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Abstract The emergence of a number of publicly avail-
able bioactivity databases, such as ChEMBL, PubChem
BioAssay and BindingDB, has raised awareness about the
topics of data curation, quality and integrity. Here we
provide an overview and discussion of the current and
future approaches to activity, assay and target data curation
of the ChEMBL database. This curation process involves
several manual and automated steps and aims to: (1)
maximise data accessibility and comparability; (2) improve
data integrity and flag outliers, ambiguities and potential
errors; and (3) add further curated annotations and map-
pings thus increasing the usefulness and accuracy of the
ChEMBL data for all users and modellers in particular.
Issues related to activity, assay and target data curation and
integrity along with their potential impact for users of the
data are discussed, alongside robust selection and filter
strategies in order to avoid or minimise these, depending
on the desired application.
Keywords Public bioactivity databases  Data curation 
Data quality
Introduction
The ChEMBL database, provided as part of a broad range
of life-science informatics resources at EMBL-EBI, is a
key representative of a current plethora of publicly
available chemical structure and bioactivity databases
(which also include, for example, PubChem BioAssay,
BindingDB, GuideToPharmacology and DrugBank) [1–7].
The emergence and increasing popularity of such databases
has arguably democratised the fields of computational
medicinal chemistry and chemical biology, and more
generally drug discovery. Large-scale access to quality data
for data-driven analyses of polypharmacology, bioisosteric
replacements, chemogenomics, drug repurposing and pre-
dictive modelling are no longer the exclusive privilege of a
few commercial organisations [8–14]. Moreover,
ChEMBL’s open nature, as reflected in its clear data
licensing terms, has brought about a dramatic shift in the
way the drug discovery community deposits, shares and
consumes experimental data, thus forging data exchange
activities, collaborations and pre-competitive initiatives
across industry, small and medium-sized enterprises
(SMEs), charitable organisations and academia [15–18].
ChEMBL covers a broad range of curated and annotated
data, mostly manually extracted from the primary medici-
nal chemistry literature. The data include experimental
biological readouts, such as binding, functional, absorption,
distribution, metabolism, and excretion (ADME), as well
as toxicity assay measurements. Importantly, a curated
linkage between indexed 2D chemical structures and bio-
logical targets is provided, whereby measurements are
standardised to common types and units, where possible.
The targets range from single proteins, to protein com-
plexes, sub-cellular components, cell-lines, then tissues and
finally whole organism in vivo data. In addition to the
literature-extracted information, ChEMBL also integrates
deposited screening results from PubChem Bioassay [4],
along with information on approved drugs, late-stage
clinical development candidate drugs, and their likely
efficacy targets. ChEMBL also serves as an open data-
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sharing hub for the important field of neglected tropical
diseases (NTD) research. The ChEMBL database is upda-
ted on a regular basis and, as of March 2015, the current
version (version 20) contains more than 13 million
experimentally derived bioactivities. For comprehensive
reviews of ChEMBL with regard to content, coverage,
availability and applications, the reader is referred else-
where [1, 2, 19].
The increase in the use of ChEMBL, along with other
bioactivity databases, was followed by an increase in the
community’s awareness of the topics of data integrity and
quality [20]. As a direct result, there have been several
publications on such topics in the last few years. Even
before the ChEMBL database was established, Fourches
et al. [21] were among the first to systematically codify and
document common sources of errors in public datasets and
databases in the context of chemoinformatics and QSAR
modelling research. Their review focussed on the quality of
chemical structures and exemplified typical sources of
errors and discrepancies such as treatment of tautomerism,
aromaticity, salts and functional group standardisation.
More recently, Tiikkainen et al. [22] have systematically
analysed and compared the inconsistencies introduced
during the extraction, digitalisation and subsequent cura-
tion of the data in three major commercial and publicly
available sources of bioactivity data, including ChEMBL
(version 14), Liceptor and WOMBAT. The authors
looked at cases where, for the same bioactivity data point,
two sources agreed in terms of ligand structure, biological
target assignment, activity value and activity type but
where the third did not. The analysis indicated that the
most frequent source of discrepancies was the structure of
the ligand, followed by the target assignment, the activity
value and finally the activity type—this trend would be
expected by the inherent complexity of the corresponding
data objects. More importantly, all accurate discrepancies
were communicated to the ChEMBL curation team and
were corrected in subsequent releases of the database.
In addition to the errors introduced during the data
extraction and digitalisation step, there are inherent dis-
crepancies and ambiguities in the publications themselves.
Some of these may be identified by means of automated
large-scale data mining. Kramer et al. [23] analysed Ki data
derived from ChEMBL (version 12) in order to quantify
the experimental uncertainty of independent measurements
for the same ligand–protein pair, and thus define the
maximum unbiased performance of in silico models.
During this effort, the authors identified several types of
putative activity issues and errors, listed below:
• Unrealistically high or low activity values
• Multiple values for the same ligand–protein pair
derived from a single publication
• Multiple citations of a specific activity value (exact or
rounded) for the same ligand–protein pair across
several publications leading to redundancy
• Unit transcription and conversion errors
Notably, some of these are not data errors per se: for
example, the apparent existence of multiple measurements
for the same ligand–protein pair within a paper often arises
when authors have reported activity measurements for
racemic mixtures, as well as for the isolated but structurally
uncharacterised individual stereoisomers (e.g., Figure 3a in
[23]). Similarly, repeat citations of single activity mea-
surements across multiple publications might not be con-
sidered to be an error, but can nevertheless lead to
statistical artefacts during the data modelling process. The
issues listed above were communicated to the ChEMBL
data integration team and were subsequently retrospec-
tively flagged in the ChEMBL database, as described in
detail in the sections below. In addition, the ChEMBL
database schema and interface were appropriately updated
to accommodate the results of this large-scale automated
curation effort.
In a follow-up review, the same authors discussed data
quality in bioactivity and chemogenomics databases [24].
In addition to the issues identified above, the authors
highlighted cases related to inaccurate or insufficient target
assignments, along with insufficient information in assay
description, which prevents users from comparing mea-
surements for the same ligand-target pairs across different
assays. These topics are critically discussed in the fol-
lowing sections, whereby the focus in on the activity, assay
and target curation and associated issues in the ChEMBL
database. For a review and discussion on the compound
curation and representation issues in public bioactivity
databases, the reader is referred elsewhere [20, 28]. Table 1
summarises common types of errors and ambiguities found
in bioactivity databases.
Activity, assay and target curation in the ChEMBL
database
The initial extraction of bioactivity data from the scientific
literature is performed manually and aims to capture data
as reported in a particular publication (i.e. the compounds,
measurement types, units and values as provided by the
author). The sections below provide an overview of the
further manual and automated approaches that take place
in-house and aim to standardise, curate, flag, map and
annotate activity, assay and target data in ChEMBL. Fur-
thermore, each of the respective sections is followed by a
discussion on related data integrity and ambiguity issues
and how these can be identified and minimised or avoided
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by the database user. A schematic summary of the steps
currently involved in the curation of literature data in
ChEMBL is provided in Fig. 1 below.
The activity values curation process
One problem faced in the extraction of published bioac-
tivity data is the diversity of measurement and unit types
used. For example, the ChEMBL measurement types
IC50 and clearance have each been extracted from the
literature associated with more than one hundred different
published units. These activity types, units and values are
respectively captured as ‘PUBLISHED_’ in the ACTIV-
ITIES table (Fig. 2), in order to aid users in mapping data
back to the original publication. However, comparison of
data across different publications would then require the
time-consuming and error-prone step of unit conversion
by individual users. To address this need, a standardisa-
tion workflow has been designed and implemented. For
key activity types in ChEMBL, a preferred unit or small
set of units of measurement have been selected, as cap-
tured in the ACTIVITY_STDS_LOOKUP table (Fig. 2).
Subsequently, extensive sets of unit conversion rules have
been manually compiled and employed to standardise the
data. IC50 and EC50 measurements, for instance, are
converted either to nM or lg 9 mL-1 units, depending
on the form of the original published units. Similarly,
different descriptions of the same activity type (e.g.,
‘Elimination half life’, ‘Half life’, ‘half-life’, ‘T1/20, t1/2’,
and ‘t(1/2)’) are also normalised to a single one. This
activity type and unit standardisation step has enabled the
conversion of activity values recorded in the literature
with 133 different concentration units to consistent nM
values. Likewise, AUC (Area Under the drug concentra-
tion time Curve) data with 83 units has all been stan-
dardised to units of ng 9 h 9 mL-1. Examples of the
numbers of published to standard activity types and
published to standard units are shown in Table 2a, b,
respectively. Moreover, records with activity types such
as pKi and logIC50 are converted to their unlogged
standard value and corresponding unit and relation.
Finally, the standardised activity types are mapped to
BioAssay Ontology (BAO) result terms [30, 31] and the
standardised units to unit ontology and quantities, units,
dimensions and data types (QUDT) terms [32, 33]. These
ontology mappings formalise the meanings of the activity
types and units, preventing ambiguities in their interpre-
tation, and also allow more advanced queries of the data,
such as grouping different concentration–response end-
points based on BAO.
In addition to the standardisation and mapping effort
described above, there has been a significant on-going
effort to capture the activity curation knowledge and
experience and distil it into a number of steps that can be
run in an automated fashion. The aim of this workflow is
twofold: (1) to flag activity records with potential quality
issues, mainly introduced by the publication authors or
extraction process; (2) to further standardise the activity
records, thus making them more accessible and suitable for
large-scale data mining and comparative analyses. The
flags and comments are primarily added to the DATA_-
VALIDITY_COMMENT column in the ChEMBL data-
base production schema (Fig. 2). Since ChEMBL version
15, the resulting workflow has been run before each
ChEMBL release and further activity type and unit stan-
dardisations are regularly added to this auto-curation
pipeline. The automated activity curation workflow is
summarised in Table 3.
The workflow starts with flagging missing data, i.e. data
without a published activity value or activity comment.
Then, records with unusual units for their respective
activity types are flagged by looking-up an in-house cura-
ted list of standard types and their corresponding units. As
an example, concentration-based activities, such as mini-
mum inhibitory concentration (MIC) IC50 and Kd, featur-
ing irrelevant, unknown or null associated units are flagged
in this step.
Table 1 Sources of errors and ambiguities related with bioactivity databases
Error source Examples References
Experimental Compound purity and stability [21, 25]
Errors in compound vendor catalogues. Errors in cell-line identity
Data extraction Missing stereochemistry or functional group [20, 26]
Incorrect or incomplete target assignment
Author of publication Insufficient assay description. Citation of previously reported activity values [23, 27]
Wrong activity type and units. Incorrect data processing
Database user Merging activities from different assays [21, 23, 28, 29]
Dealing with censored data points, tautomers, prodrugs, salts and duplicates
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The third step involves the further standardisation of
records with activity types, such as pKi and logIC50, which
are converted to their unlogged standard value and corre-
sponding unit, including exact and censored values. This
affects more than 20 % of the activities in ChEMBL and
‘unlocks’ a significant number of data, which are then
accessible and readily comparable for large-scale data
mining. Furthermore, at this stage, the standard activity
values that are lower than 10 are rounded arithmetically to
3 significant figures. The remaining values are rounded to
the second decimal digit.
With the majority of the records having standardised
values and units, the next step in the workflow flags records
that have unusually low or high activity values for their
type and unit. This is achieved by looking-up an internal
list of normal value ranges, compiled and maintained by in-
house curators. It should be noted that the defined normal
ranges used in this process are fairly stringent (e.g.,
0.01 nM–100 lM for IC50/Ki values) and some data fall-
ing outside of these ranges may be correct. A special case
is made for binding affinities that involve fragments
(MW\ 350) as reported in relevant fragment screening
Fig. 1 The current in-house compound, activity, assay and target
curation workflow in ChEMBL production. The steps involved in the
activity, assay and target curation branches, along with suggestions on
how the users/modellers can utilise these to improve data integrity
and minimise or avoid ambiguity are discussed in the following
sections
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publications; these are likely to be genuinely lower. Such
cases are treated with more relaxed activity ranges.
The fifth and sixth steps aim to detect and flag duplicate
entries and potential transcription errors in activity records
that come from different publications, whereby a process
similar to the one reported by Kramer et al. [23] is followed.
Putative duplicated entries are records with identical com-
pound, target, activity, type and unit values that were most
likely reported as citations of measurements from previously
published papers, even when these measurements were
subsequently rounded. Transcription errors consist of
otherwise identical entries, whose activity values differ by
exactly 3 or 6 orders of magnitude, thus indicating a likely
error in the units (e.g., lM instead of nM).
The final step of the workflow involves the calculation
of the pChEMBL value (the negative logarithm of the
activity values (in M units)) for records with dose–response
activity types, such as IC50, XC50, EC50, AC50, Ki, Kd,
and Potency and where there are no data validity
comments.
Fig. 2 The experimental data section of the ChEMBL 20 database schema, showing the columns of the ACTIVITIES and ASSAYS tables
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Activity records curation: discussion
Although the error rates in activity value and type are rela-
tively lower than target mapping or structure representation
[22], they may introduce ambiguity and be detrimental to the
robustness of generated statistical learning models and
activity summarisation efforts [23, 27]. Often for instance,
the calculation of the median or mean activity value for a
compound-target pair is the first step for the generation of a
QSAR regression model. This summary figure will be
significantly skewed by the presence of transcription errors
and/or unrealistically lowor high activity values.At the same
time, confidence in an activity value may be overestimated
due to citation-related over-sampling, as opposed to truly
independent measurements.
It has to be highlighted here that errors such as duplicate
values and unit transcription errors are sometimes inad-
vertently introduced by the authors of the publications. For
example, it is common practice for authors in the medicinal
chemistry literature to include tables in which they cite
measurements for reference compounds, such as known
tool compounds or drugs. These citations refer to previous
papers often reporting different assay protocols and activity
units, which are then misquoted in the table. This is clearly
illustrated in the case of two publications [34, 35] from the
same corresponding authors, who mis-cite a number of Ki
activity values with the wrong units for two assays and
several reference compounds (Table 1 in both publica-
tions). This has lead to otherwise matching activity records
with 1000-fold activity value difference being recorded in
the database. After the activity records curation step, the
corresponding records from the later publication are flag-
ged as ‘potential transcription errors’ in the DATA_VA-
LIDITY_COMMENT of the ACTIVITIES table.
While manually checking all publications for cited
duplicate values or transcription errors would be an
impossible task, the existence of multiple measurements
for the same compound and target facilitate automated
approaches to identify such inconsistencies and outliers in
the data. The automated activity curation workflow com-
plements the manual curation performed by the in-house
biological curation experts. Its aim is not to delete activity
records but merely to flag potential and putative issues,
inherently found in publications or potentially introduced
by the data extraction process. By incorporating the flags in
the DATA_VALIDITY_COMMENT and POTENTIAL_-
DUPLICATE columns in their analysis procedures, the
interested user/modeller may adjust appropriately the
granularity in the validity of the activity data, based on the
scale and type of the desired data mining application;
examples include local or global QSAR modelling
Table 2 Number of distinct published activity units (a) and activity
types (b) mapped to standard, normalised units and types, respec-
tively, after the standardisation step
Number of distinct published activity units STANDARD_Unit
(a)
133 nM
83 ng 9 h 9 mL-1
56 lg 9 mL-1
36 lM 9 h
28 mL 9 min-1 9 kg-1
20 mL 9 min-1 9 g-1
17 mg 9 kg-1
16 lmol 9 g-1
15 h
10 L 9 kg-1












Table 3 The activity records curation workflow along with the count and percentage of affected records in ChEMBL 20
Order Step Data validity comment Num. and % affected records
1 Flag missing activities ‘Potential missing data’ 12,263—0.09 %
2 Flag non-standard units for activity type ‘Non standard unit for type’ 81,060—0.6 %
3 Convert log activity values N/A 2.6 9 106—20.3 %
4 Flag out of range values ‘Outside typical range’ 187,108—1.7 %
5 Flag potential duplicate values N/A 64,860—0.48 %
6 Flag potential transcription errors ‘Potential transcription error’ 382—0.003 %
7 Calculate standard negative log values N/A 2.8 9 106—20.7 %
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(regression or classification), chemogenomics modelling or
matched molecular pair analysis. As it has been suggested
before [21, 26], data preparation and filtering is equally, if
not more important, than the analysis or model itself.
In parallel, additional annotation with the pChEMBL
(negative logarithm of activity in M) value adds more
coverage and leverage to the activity data; this allows for
comparisons across assays, publications and activity types
for a given compound-target pair, which is suitable for
larger scale data integration and modelling, such as ligand-
based target prediction [9, 36, 37]. In the case of mixing
heterogeneous pIC50 and pKi data, there is evidence that
this does not lead to loss of quality, given that certain
criteria are met [27].
The assay curation process
Curation of assays in ChEMBL focuses on capturing key
characteristics of the experiment that has been performed
(such as the assay type, format and cell-line/tissues used)
and the assignment of targets (discussed in the next section).
Spelling correction is first performed on assay descriptions
in order to correct commonly misspelled words and there-
fore improve search and query recall. Next, each assay is
assigned an ASSAY_TYPE which can take one of five
values: B (binding), F (functional), A (ADME), T (toxicity)
and P (physicochemical). Since these categories are not
necessarily mutually exclusive, an order of precedence may
be applied. For example, a cytochrome P450 3A4 binding
assay could potentially be assigned a type of either B or A,
but is generally assigned to the ADME category, as this is
considered to be more informative in allowing users to
identify and filter relevant data. Similarly, a cytotoxicity
assay could be either a functional assay (in the context of a
cancer) or a toxicity assay (when assessing whether a
compound has adverse toxic effects). Cell-lines used in
assays are extracted from assay descriptions and mapped (in
the ChEMBL CELL_DICTIONARY) to existing published
ontologies, such as the experimental factor ontology (EFO)
and the cell line ontology (CLO) [38, 39]. This process can
be complicated by the fact that cell lines may not always be
adequately described in the original publication in order to
allow unambiguous identification. The term ‘H4’, for
example, can variously be used to refer to either a rat
hepatoma cell line (ATCC CRL-1548), or a human neu-
roglioma cell-line (ATCC HTB-148). Work is also
under way to extract organ/tissue information for assays
and map to the appropriate Uberon ontology terms [40].
Finally, a rule-based classifier is used to determine the assay
format, according to the BioAssay Ontology (e.g., bio-
chemical, cell-based, tissue-based, organism-based).
Capture of assay details: discussion
A frequent criticism of the ChEMBL database is a lack of
detail captured regarding the assay protocols. Such infor-
mation is important as it allows users to reliably compare
assays conducted in different labs for the same compound
or biological target. While key details of the assay are
typically captured in the assay description, the need for
more structured representation of such data is recognised.
Therefore, a mechanism to allow more robust capture of
these in the ASSAY_PARAMETERS database table
(Fig. 2) has been recently implemented, in anticipation of
future, more complete bioassay reporting [41]. Information
such as the concentration or dose at which a compound has
been tested, administration route for an in vivo assay, or
time point at which the measurement was taken can now be
captured, where such information is available. Details such
as mutations within the protein target (which could greatly
affect compound activity) or the use of particular assay
constructs such as chimeric proteins could also be captured
in this way. Currently, the target assigned in ChEMBL
represents the full-length, wild-type protein but details of
mutations may be captured in the assay description. An
example of one of the limitations here is that of thrombin
for which the initially produced protein is in a pre-pro
form, i.e. has a secretion signal, and after cleavage of this
signal sequence, circulates in a catalytically inactive form,
in which ligand binding for most classes of inhibitors does
not occur. Additionally, activity of mature thrombin, fur-
ther depends on various ion-binding and post-translational
amino-acid modifications. Future plans also include the
extraction of assay parameters from existing assay
descriptions by means of text mining, where possible, so
that they can be queried more effectively, as well as
seeking to capture these details for future additions to the
database.
All the annotations described above will all aid users in
filtering the ChEMBL data to the kind of assays they are
interested in (e.g., retrieve all organism-based ADME
assays with a particular activity type such as clearance, or
all cell-based cytotoxicity assays using mouse 3T3-L1
cells). However, it should be noted that it will still likely
not be possible to annotate assays to the level of detail that
would allow determination of whether two independently
conducted assays are truly identical in protocol (for
example the detection instrument with which the mea-
surements were taken, the full composition of the buffer
used). Many of the journals from which data are extracted
do not require details of assay protocols to be included
where these have previously been published. Therefore, for
a given article, the relevant information may be contained
in another cited article (which may, in turn, cite other
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earlier publications). While essential assay details are
extracted from these cited publications, where available, to
extract more fine-grained assay details at large scale would
be prohibitively time-consuming and expensive. It should
also be noted that even when assay conditions appear to be
the same, significant variability is observed between mea-
surements taken in different labs [27].
For the reasons described above, users should therefore
consider the assay annotation provided in ChEMBL as a
filter to remove assays that are clearly not comparable,
rather than a guarantee that two assays are comparable. It is
always advisable to consult the original publications and
obtain further information regarding the experimental setup
where such details are considered of great importance. On
the other hand, for large-scale applications, the size of the
data set may be sufficient that division of assays into
broadly similar subsets (e.g., biochemical vs. cell-based)
may be robust enough to yield useful results.
The target curation process
To achieve one of the main aims of ChEMBL, i.e. coupling
ligand-regulated phenotypic effects to the genotype, it is
necessary to assign each assay to a target, wherever
possible. Within a publication, the target of an assay is
usually only referred to by a name or abbreviation, rather
than a database identifier. Additional curation effort is
therefore required to determine the molecular identity of
the target and assign this a unique ChEMBL target iden-
tifier listed in the TARGET_DICTIONARY table (Fig. 3).
While UniProt is used as the reference source for protein
sequences and identifiers within ChEMBL [42], an
important distinction between the concept of a ‘protein’
and a ‘target’ is made: a target is defined as the entity with
which the compound actually interacts in a particular assay
system, which could be a protein complex, or a non-protein
target such as DNA, for instance. This requires the creation
of unique identifiers for these targets. While identification
of the correct target is relatively trivial for some kinds of
assays, in other cases the assignment can be much more
complex. Within ChEMBL, a range of different target
types are captured, depending on nature of the molecular
entity assigned and confidence in assigning it. The criteria
for assigning some of the common target types are dis-
cussed below. Each target is then associated with each of
its individual molecular components (usually proteins) and
these components are further annotated with information
such as the protein family to which they belong, in order to
facilitate searching and further grouping of the data.
Fig. 3 A subset of the target
information section of the
ChEMBL 20 database schema
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Biological complexity in target assignment:
discussion
For a binding assay carried out on a single, isolated protein
in vitro, it is usually trivial to unambiguously assign the
correct target. However, such data represent only around
10 % of the activity measurements in the ChEMBL data-
base. Far more common are functional assays carried out in
cell-lines, tissues or whole organisms. In these complex
systems the activity of a tested compound may be much
harder to interpret, yet will also yield more valuable
information regarding the efficacy of the approach. In cell-
based assays, a target of interest is often overexpressed or
the assay may be carried out using a competing ligand with
known selectivity for that target. In these cases, the intended
molecular target of the assay may be assigned, although this
assignment should still be interpreted with some caution, as
there could be other proteins or pathways within the cell-
line contributing to the observed effect. In many other cases
though, the molecular target responsible for the effects of
the compound cannot be unambiguously determined. For
example, a common assay for muscarinic acetylcholine
receptor-mediated smooth muscle contraction involves the
use of guinea pig ileum. While the M3 receptor subtype is
now believed to be primarily responsible for this effect [43],
this information was not known at the time many of these
assays were performed, and other receptor subtypes are also
present in the tissue—notably M2 receptors, which are more
abundant than M3 receptors [44]. Similarly, many other
functional assays potentially measure activity against a
group of closely related proteins, thus identification of the
receptor subtype(s) or enzyme isoform(s) contributing to
the effect may not be possible. Mapping such assays to a
single protein may be an oversimplification of the biology
involved, while mapping the assay to each of the individual
protein family members (as was originally done in
ChEMBL) may mislead users, giving the impression that
each subtype has been tested individually (though even in
earlier versions of the database, a flag was present to allow
users to detect this ‘multiple’ mapping). To deal with such
situations where one cannot be sure of the precise molecular
identity of the target, ChEMBL assigns a ‘PROTEIN
FAMILY’ target, incorporating each of the possible family
members. Annotating assays in this way still allows
retrieval of potentially valuable data for users interested in a
particular protein or protein family and wishing to include
functional/phenotypic endpoints in addition to binding
measurements, but also allows the exclusion of such data
where a precise mapping is important (for example, training
predictive models or assessing compound selectivity).
An additional level of complexity originates from the
fact that many of the molecular targets of bioactive
compounds are not single proteins but protein complexes.
While in some cases it may be possible to identify the
subunit of the complex to which the compound binds, in
other cases compounds may bind to the interface between
two subunits, or the identity of the binding site may not be
known. Even when the binding subunit is known, for many
applications it may be important to understand the com-
position of the full protein complex. For example, activity
may only be observed in a functional assay if all of the
required subunits are present, potentially leading to false
positive results if this information is omitted. Again,
mapping an assay where the target is a protein complex to
each of the individual subunits could be misleading to
users, suggesting that the compound might have activity
against each of the subunits in isolation. This could con-
found various analyses, such as the assessment of drug-
gability. Therefore such assays are mapped to a ‘PROTEIN
COMPLEX’ target in ChEMBL. Furthermore, the data
model also allows for the annotation of the binding subunit
(or also a structural domain within a subunit) within the
target, where known; this is annotated for targets of
approved drugs.
It is also important to note that the two situations descri-
bed above are not mutually exclusive and it is quite possible
(and indeed common) to have activity measured in a cell or
tissue-based assay where the intended target is known to be a
protein complex, but the precise subunit composition is
unknown. Perhaps the most common example of this is the
measurement of binding to GABA-A receptors in rat brain
membranes. GABA-A receptors are pentameric complexes
consisting of various combinations of alpha, beta and gamma
subunits. Furthermore, there are six subtypes of alpha sub-
unit, three subtypes of beta subunit and three subtypes of
gamma subunit,making a large number of different receptors
possible. Both alpha and beta subunits are necessary for
binding of the endogenous ligand, GABA, while many
GABA-A receptor drugs (benzodiazepines) bind at alpha/
gamma subunit interfaces. Certain receptor combinations
appear to be restricted to discrete areas of the brain, while
other regions express a diversity of receptor types [45]. Such
cases are assigned a target type of ‘PROTEIN COMPLEX
GROUP’ in ChEMBL, indicating that the caveats associated
with both the ‘PROTEIN COMPLEX’ and the ‘PROTEIN
FAMILY’ target type apply.
A further challenge in target assignment can be the
identification of suitable protein sequences for inclusion.
Not all species that have bioactivity data in ChEMBL have
been fully genome-sequenced, and therefore it might not be
possible to identify the correct protein in UniProt. In such
cases an orthologous protein might be substituted (e.g., a
human sequence in place of another mammalian target, or a
model organism, such as E. coli, in place of another
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bacterial species). A RELATIONSHIP_TYPE field in the
ASSAYS table (Fig. 2) indicates cases where the target
assigned is a homologue (‘H’) of the actual assayed target.
Again, it may be appropriate for users to filter out such data
in certain circumstances.
In analysing and using ChEMBL data, it is therefore
important for the user/modeller to consider which types of
data are suitable for addressing the question of interest, to
select only appropriate target types and to understand the
relationship of these targets with each of their individual
protein components. Users should also be aware that other
databases integrating data from ChEMBL, whose data
models differ, might not represent or display this, or other
data in the same way.
Conclusion and future outlook
The availability of public chemistry and bioactivity data-
bases, along with large scale data-driven applications has
increased the community’s attention to data curation and
integrity issues, such as structure quality, name-to-structure
fidelity, structure–activity mapping, activity data accuracy,
assay description sufficiency, target assignment, author
errors and redundancy. Better quality data mean more and
higher confidence assertions and therefore more robust
applications and models. In this work, the focus was on the
activity, assay and target curation and associated issues.
Current strategies to map, standardise, flag and further
annotate the data were presented, along with recommen-
dations on good practice when mining these. Notably, the
efforts reported here are only a subset of the on-going in-
house manual and automated curation, which include
compound structures, compound synonyms and drug
information. Future plans include more detailed extraction
of terms and parameters from the assay description, stan-
dardisation of additional activity types (particularly in the
areas of pharmacokinetic, toxicity and crop protection
data) and the addition of further BAO mappings, such as
the bioassay class (e.g., radioligand-binding assay, cell
growth assay, cytotoxicity assay), facilitating more granu-
lar queries particularly against phenotypic assays. From a
technical point of view, we aim to streamline the curation
process, in order to accelerate the ChEMBL release cycles
and enable better data validation and easier data deposi-
tions by users. Finally, in the longer run, we envisage
broadening the access and scope of the curatorial process
by providing a simple data-quality feedback mechanism in
the ChEMBL interface, and eventually developing a pub-
licly available curation interface. Such an interface could
serve as a platform to curate either ChEMBL data, perhaps
even in a crowd-sourcing manner, or in-house, proprietary
data, according to standardised curation rules. Finally,
some of the sources of potential error the and accompa-
nying burden of curation could be reduced in future by the
enforcement of standards for data recording [41] and
mandates by journals to deposit bioactivity data in a public
repository at the point of publication.
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